Advocate
Resource hub for campaigns, advocacy materials, and tools developed by hepCoalition and partner organizations that can be adapted and used by advocates for local campaigns in their own contexts.
Campaigns
Campaigns include the ongoing efforts that aim to expand affordable treatment and diagnostics access for all who need it.
Liberate Generics!
Ongoing, global campaign working to accelerate equitable access to affordable, generic hepatitis C treatments. More
- About the Campaign
- Gilead’s License on Hepatitis C Drugs, Sofosbuvir and Ledipasvir: a Fool’s Bargain
- Doctors of the World Opposes the Patent on Sofosbuvir
- APN+ Joins MTAAG+ in Congratulating Malaysia on Sofosbuvir Compulsory License
- Hepatitis C Cure, Sofosbuvir, Turns 5 Years Old: The Vast Majority of People Still Nave Not Been Treated
- Activists Demand Affordable Hepatitis C Treatment
- First Hepatitis C Treatment Developed Through South-South Cooperation Registered in Malaysia
- Gilead’s Claim That Generic Purchase of Sofosbuvir Would Lead to Patent Infringement in Brazil Dismissed
- Sofosbuvir Case in Brazil
- LAT CAB Calls on AbbVie, Licensed Generic Manufacturers of G/P, and the Medicines Patent Pool to Fulfill their Commitment to Make Generic HCV Treatment Widely Available
- Treatment for Hepatitis C: The Patent System is Standing in the Way of Access to Medicine
Have a Heart, Save My Liver!
Ongoing, global campaign focusing on where the registration of diagnostics and direct-acting antivirals has stalled as well as the slow treatment uptake in low- and middle-income countries. More
- About the Campaign
- Have a Heart, Save My Liver!: Where Are My Diagnostics?
- Who Has Access to Hepatitis C Testing? Liberate Our Diagnostics!
- Access to Hepatitis C Treatment and Care Among People Who Inject Drugs: Failing People Most Disproportionately Affected
- Have a Heart, Save My Liver! Where is the Cure Registered?
- Have a Heart, Save My Liver! Which Countries Restrict Treatment?
- Have a Heart, Save My Liver! Why Hepatitis C Virus Care Remains Inaccessible
Take Action!
The section includes sign-on letters, petitions, and collective statements.
Drug Policy Manifesto for the 2024 European Parliament Elections
For a drug policy that makes Europe safer, healthier, and more just! A Manifesto, initiated by C-EHRN, lays down a vision for a pragmatic, innovative, and human rights-centred European drug policy. More
The Amsterdam Manifesto: A Catalyst for Change in Drug Policy
A diverse coalition of policymakers, scientists and civil society representatives unite in creating more humane drug policy by prioritizing the well-being of all impacted by the multifaceted challenges of illegal drug markets. Endorse NOW! More
Advocacy Tools
Advocacy materials and tools developed by hepCoalition and partner organizations that can be adapted and used by advocates for local campaigns in their own contexts. Includes training materials, community monitoring/data collection, and graphics.
Creating Safer Consumption Spaces in Europe: Evolving Contexts and Implications for Policy
C-EHRN releases a policy brief providing an overview of the state of the art regarding Drug Consumption Rooms, as well as an overview of recommendations and examples of good practices for policymakers. More
The Cost of Complacency: A Harm Reduction Funding Crisis
Harm Reduction International releases its annual report exploring the state of harm reduction funding in low- and middle-income countries. More
Policy Statements
The section includes partners’ policy and advocacy statements that can aid activists in their messaging and calls to action.
Time for Change: Advancing New Drug Policies That Uphold Human Rights
To mark the Global Day of Action, 26 June, of the Support. Don’t Punish campaign, Amnesty International releases a policy paper to contribute to the advancement of drug policies that better uphold human rights. More
2024 Manifesto for a Progressive EU Drug Policy
For a drug policy that makes Europe safer, healthier, and more just! A Manifesto, initiated by C-EHRN, lays down a vision for a pragmatic, innovative, and human rights-centred European drug policy. More